RxDoctor Payments DataLook up a doctor →

Jerry Smartt, MD

Neurology · Carmel, INNPI 1306850722

Payments from drug & device makers

$253,512in general payments, 2019–2025

Across 1,454 payments — averaging $174.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$190K
  • Biohaven Pharmaceutical Holding Company Ltd.$22K
  • Pfizer$10K
  • Genentech USA, Inc.$7K
  • Biohaven Pharmaceuticals, Inc.$4K
  • Livanova USA, Inc.$3K
  • plus $18K from 54 others

What the payments were for

  • Consulting fees$8,9864%
  • Speaking & faculty fees$210,25883%
  • Travel & lodging$6,6013%
  • Food & beverage$26,78911%
  • Education$8790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)507$189,874
Biohaven Pharmaceutical Holding Company Ltd.49$22,408
Pfizer29$9,504
Genentech USA, Inc.41$6,891
Biohaven Pharmaceuticals, Inc.30$4,317
Livanova USA, Inc.13$2,624
Teva Pharmaceuticals USA, Inc.82$1,570
Amgen47$1,274
EMD Serono, Inc.38$1,137
Harmony Biosciences LLC29$1,063
Novartis63$943
UCB, Inc.33$913
Eisai Inc.28$742
Acadia Pharmaceuticals Inc17$683
Vanda Pharmaceuticals Inc.20$666
MDD US Operations, LLC21$619
Axsome Therapeutics, Inc.19$605
Lundbeck LLC26$591
Lilly USA, LLC37$565
Supernus Pharmaceuticals, Inc.59$534
Neurocrine Biosciences, Inc.23$506
Sanofi14$420
Argenx US, Inc.7$419
Sunovion Pharmaceuticals Inc.37$397
SK Life Science, Inc.23$391
Amneal Pharmaceuticals LLC14$354
CSL Behring13$322
Johnson & Johnson11$309
Merck18$301
AstraZeneca(2 entities)8$264
Jazz Pharmaceuticals Inc.7$209
Biogen7$185
Bristol Myers Squibb9$179
Otsuka America Pharmaceutical, Inc.3$153
Takeda Pharmaceuticals U.S.A., Inc.4$137
Arbor Pharmaceuticals, Inc.7$133
Daiichi Sankyo Inc.2$128
E.r. Squibb & Sons, L.L.C.1$104
Avanir Pharmaceuticals, Inc.5$94
Upsher-smith Laboratories LLC5$93
Tanabe Pharma America, Inc.4$92
Almatica Pharma LLC5$81
Sumitomo Pharma America, Inc.5$64
Aprecia Pharmaceuticals, LLC3$53
Ironshore Pharmaceuticals Inc.3$52
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$52
Bausch Health US, LLC3$51
TG Therapeutics, Inc.3$51
Scilex Pharmaceuticals Inc.2$48
Merz Pharmaceuticals, LLC2$43
Neurelis, Inc.2$41
Genentech, Inc.1$40
Avadel CNS Pharmaceuticals, LLC1$33
GRT US Holding, Inc.2$26
Assertio Therapeutics, Inc.1$25
Abbott1$24
Promius Pharma LLC1$22
Banner Life Sciences, LLC1$20
Octapharma USA, Inc.1$17
Collegium Pharmaceutical, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$253,512 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$51,889
Medicare patients
100
Services billed
1,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant49$85,698
QuliptaAtogepant40$50,446
Nurtec OdtRimegepant Sulfate25$40,442
LinzessLinaclotide57$36,251
RexultiBrexpiprazole16$33,871
BotoxOnabotulinumtoxina25$31,397
Aimovig AutoinjectorErenumab-Aooe21$31,279
RytaryCarbidopa/Levodopa16$25,907
Emgality PenGalcanezumab-Gnlm22$20,616
SunosiSolriamfetol Hcl24$20,599
VraylarCariprazine Hcl13$18,590
Lidocaine32$13,429
LyricaPregabalin15$11,580
OxycontinOxycodone Hcl13$10,613
TrintellixVortioxetine Hydrobromide13$6,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Linzess, Botox, Vraylar$189,874$222,381184 claims
PfizerNurtec Odt, Lyrica$9,504$52,02240 claims
Otsuka America Pharmaceutical, Inc.Rexulti$153$33,87116 claims
Amneal Pharmaceuticals LLCRytary$354$25,90716 claims
Axsome Therapeutics, Inc.Sunosi$605$20,59924 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$137$6,28813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Indiana.

Other neurology in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →